Head-to-head evidence
Risperidone (Risperdal) vs Risperidone (Rykindo)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Risperidone (Risperdal)
Marketed by Johnson & Johnson
NCT00253136 · Phase 3 · completed
The study randomized 458 participants to double-blind risperidone or placebo, with change in the clinical PANSS score as the primary endpoint. Because the registry does not report whether this endpoint was met, the trial provides a well-controlled design but no assessable result.
Next expected readout: December 2026 · NCT06482554 (registry estimate)
Risperidone (Rykindo)
Marketed by Luye Pharma Group
NCT02055287 · Phase 1 · completed
A non-randomized, open-label, four-dose pharmacokinetic study of Rykindo in 36 participants. With no randomization, no blinding, no comparator arm, and no results posted to the registry, this is weak evidence.
Next expected readout: December 2027 · NCT07047651 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Risperidone (Risperdal)'s landscape · Risperidone (Rykindo)'s landscape